Understanding obesity-hypoventilation in patients with metabolic syndrome
Prevalence of Obesity-hypoventilation Syndrome in Patients With Metabolic Syndrome.
This study looks at how common obesity-hypoventilation syndrome is in people with metabolic syndrome to better understand their breathing problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | SOS Oxygene Mediterranee Industry-sponsored |
| Locations | 1 site (Bondigoux) |
| Trial ID | NCT04839419 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the prevalence of obesity-hypoventilation syndrome among patients diagnosed with metabolic syndrome. Participants will undergo a series of assessments including functional respiratory exploration, arterial blood gas analysis, and overnight polygraphy coupled with capnography. The study seeks to gather data that could enhance understanding of respiratory complications associated with obesity in this patient population.
Who should consider this trial
Good fit: Ideal candidates are individuals with a body mass index (BMI) greater than 30 kg/m2 who are not currently receiving CPAP or NIV treatment.
Not a fit: Patients with obstructive respiratory diseases or untreated cardiac dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients suffering from obesity-hypoventilation syndrome.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have indicated a growing recognition of the prevalence of obesity-hypoventilation syndrome in related populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI\>30 kg/m2 * no treatment with CPAP nor NIV Exclusion Criteria: * obstructive respiratory disease * non-treated cardiac dysfunction
Where this trial is running
Bondigoux
- Clinique du Château de Vernhes — Bondigoux, France (Recruiting)
Study contacts
- Principal investigator: Mathieu Despeaux, MD — Clinique du Chateau de Vernhes
- Study coordinator: Delphine Delample, PhD
- Email: d.delample@sosoxygene.com
- Phone: 0612155648
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.